Patent Assignment
Reel/Frame 070742/0835
Assignment of Assignor's Interest
Recorded: 2025-04-04
Pages: 18
Assignor
LIPOSCIENCE, INC.
Executed: 2024-12-20
Assignee
LABORATORY CORPORATION OF AMERICA HOLDINGS
531 SOUTH SPRING STREET, BURLINGTON, NORTH CAROLINA, 27215
Covered Properties
(71)
Methods, Systems, and Computer Program Products for Providing Personalized Lipoprotein-Based Risk Assessment Information
Application:
09/258,740 →
Methods, Systems, and Computer Program Products for Analyzing and Presenting Nmr Lipoprotein-Based Risk Assessment Results
Application:
09/291,736 →
Methods, Systems, and Computer Program Products for Analyzing and Presenting Nmr Lipoprotein-Based Risk Assessment Results
Method of Determining Presence and Concentration of Lipoprotein X in Blood Plasma and Serum
Methods for Providing Personalized Lipoprotein-Based Risk Assessments
Message Accessing
Resist composition
Application:
10/613,044 →
Publication:
US 2004/0053160
Methods, Systems and Computer Programs for Deconvolving the Spectral Contribution of Chemical Constituents with Overlapping Signals
Steel Cutting System and Method
Nmr Clinical Analyzers and Related Methods, Systems, Modules and Computer Program Products for Clinical Evaluation of Biosamples
Method and system for enabling venues to selectively block incoming calls to cellular phones present in venue premises
Application:
11/124,837 →
Publication:
US 2006/0252432
Methods, Systems and Computer Programs for Assessing Chd Risk Using Adjusted Ldl Particle Number Measurements
NMR Measurement of Clinically Relevant Ionized Biosample Constituents Such As Ionized Calcium and/or Magnesium
Methods, Systems and Computer Programs for Assessing Chd Risk Using Adjusted Hdl Particle Number Measurements
Preceramic Silazane Polymer for Ceramic Materials
Watercraft Steering System, and Watercraft
Micro and Nano-Structure Metrology
Application:
11/990,243 →
Publication:
US 2009/0304992
Nmr Analyzers for Clinical Evaluation of Biosamples
Quantitative Nmr Clinical Analyzers with Automatic Nmr Temperature Sensitivity Compensation That Accommodate Large Ambient Operational Temperature Ranges
Nmr Quantification of Tmao
NMR Measurements of NMR Biomarker GlycA
Multi-Parameter Diabetes Risk Evaluations
Protective Hdl Particle Number Evaluations
Chd Risk Stratification Evaluations for Subjects with High Levels of Large Hdl -P
Nmr Analyzers for Clinical Evaluation of Biosamples
Nmr Quantification of Tmao
Multi-Parameter Diabetes Risk Evaluations
Multiple-Marker Risk Parameters Predictive of Conversion to Diabetes
Cardiovascular Risk Evaluations Using a Risk Parameter That Includes an Hdl and Inflammatory Biomarker Interaction Parameter
Multi-Parameter Diabetes Risk Evaluations
NMR Measurements of NMR Biomarker GlycA
CHD Risk Stratification Evaluations for Subjects with High Levels of Large HDL-P
Quantitative NMR Clinical Analyzers With Automatic NMR Temperature Sensitivity Compensation that Accommodate Large Ambient Operational Temperature Ranges
Application:
15/629,926 →
Publication:
US 2017/0293007
Cardiovascular Risk Evaluations Using a Risk Parameter that Includes an HDL and Inflammatory Biomarker Interaction Parameter
Multi-Parameter Metabolic Vulnerability Index Evaluations
Methods and Systems to Detect and Quantify the Amount of LP-X and Other Abnormal Lipoproteins in a Biosample Using NMR Spectroscopy
NMR Analyzers for Clinical Evaluation of Biosamples
Multi-Parameter Diabetes Risk Evaluations
CHD Risk Stratification Evaluations for Subjects With High Levels of Large HDL-P
NMR Measurements of NMR Biomarker GlycA
NMR Analyzers for Clinical Evaluation of Biosamples
Application:
17/508,214 →
Publication:
US 2022/0043086
NMR System and Methods for Multi-Parameter Metabolic Vulnerability Index Evaluations
Cardiovascular Risk Evaluations Using a Risk Parameter That Includes an HDL and Inflammatory Biomarker Interaction Parameter
Multiple-Marker Risk Parameters Predictive of Conversion to Diabetes
Application:
18/661,461 →
Publication:
US 2024/0304336
Cardiovascular Risk Evaluations Using a Risk Parameter That Includes an HDL and Inflammatory Biomarker Interaction Parameter
Application:
18/661,491 →
Publication:
US 2024/0302389
Methods and Computer Program Products for Determining Risk of Developing Type 2 Diabetes and Other Insulin Resistance Related Disorders
Application:
60/130,612 →
Method of determining presence and concentration of lipoprotein X in blood plasma and serum
Application:
60/309,350 →
Methods, systems and computer programs for deconvolving the spectral contribution of chemical constituents with overlapping signals
Application:
60/421,177 →
Methods, systems and computer programs for assessing CHD risk using mathematical models that consider in vivo concentration gradients of LDL particle subclasses of discrete size
Application:
60/513,795 →
NMR clinical analyzers and related methods, systems, modules and computer programs for clinical evaluation of biosamples
Application:
60/558,516 →
Methods, Systems and Computer Programs for Assessing Chd Risk Using Adjusted Hdl Particle Number Measurements
Application:
60/746,894 →
NMR measurement of clinically relevant ionized biosample constituents such as ionized calcium and/or magnesium
Application:
60/758,272 →
Nmr Measurement of Clinically Relevant Ionized Biosample Constituents Such as Ionized Calcium and/or Magnesium
Application:
60/807,942 →
Insulin Resistance Risk Assessment Scores
Application:
61/106,833 →
Quantitative Nmr Clinical Analyzers with Automatic Nmr Temperature Sensitivity Compensation That Accommodate Large Ambient Operational Temperature Ranges
Application:
61/502,965 →
Protective Hdl Particle Number Evaluations
Application:
61/639,508 →
Nmr Quantification of Tmao
Application:
61/654,249 →
Cardiac Risk Assessments Using Nmr Measures of Glycoprotein
Application:
61/657,315 →
Nmr Measurements of Glyca
Application:
61/711,471 →
Multi-Parameter Risk Evaluations Using Nmr Measurements of Glyca
Application:
61/739,305 →
Nmr Quantification of Branched Chain Amino Acids
Application:
61/831,353 →
Short Term and Longer Term Diabetes Risk Evaluations
Application:
61/923,855 →
Cardiovascular Risk Evaluations with a Risk Parameter That Includes an Hdl and Inflammatory Biomarker Interaction Parameter
Application:
62/049,141 →
Methods and Systems for Predicting Colorectal Cancer Incidence and Mortality
Application:
62/345,453 →
Methods and Systems for Measuring PVX
Application:
62/555,421 →
Methods and Systems to Detect and Quantify the Amount of LP-X in a Biosample Using NMR Spectroscopy
Application:
62/584,536 →
Methods and Systems to Detect and Quantify the Amount of LP-X in a Biosample Using NMR Spectroscopy
Application:
62/589,113 →
Multi-Parameter Metabolic Vulnerability Index Evaluations
Application:
62/619,497 →
Methods to Predict Liver Disease Mortality Using Lipoprotein LP-Z
Application:
62/757,505 →
Metabolic Vulnerability Analyzed by NMR
Application:
63/395,589 →
Methods and Systems for Measuring Citrate and Creatinine Levels by NMR Spectroscopy
Application:
63/402,738 →
Related Assignments
(13)
Other recorded transfers of the patents in this record — the chain of ownership.
Security Agreement
Jun 18, 2012
From: EDW. C. LEVY CO.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 028397/0366 →
Assignment of Assignor's Interest
Dec 21, 2012
From: OTVOS, JAMES D.
To: LIPOSCIENCE, INC. (PREVIOUSLY LIPOMED, INC.); NORTH CAROLINA STATE UNIVERSITY
Reel/Frame 029683/0052 →
Assignment of Assignor's Interest
Jan 15, 2013
From: MORGAN, DAVID R.; JEYARAJAH, ELIAS J.
To: LIPOSCIENCE, INC.
Reel/Frame 029645/0419 →
Change of Name
Jan 23, 2013
From: LIPOMED, INC.
To: LIPOSCIENCE, INC. (PREVIOUSLY LIPOMED, INC.)
Reel/Frame 029683/0056 →
Assignment of Assignor's Interest
Jan 23, 2013
From: LIPOMED, INC.
To: LIPOSCIENCE, INC.
Reel/Frame 029683/0044 →
Change of Name
Jan 25, 2013
From: LIPOMED, INC.
To: LIPOSCIENCE, INC. (PREVIOUSLY LIPOMED, INC.)
Reel/Frame 029698/0924 →
Assignment of Assignor's Interest
Jan 25, 2013
From: OTVOS, JAMES D.
To: LIPOSCIENCE, INC.; NORTH CAROLINA STATE UNIVERSITY
Reel/Frame 029698/0920 →
Assignment of Assignor's Interest
Feb 10, 2014
From: NOKIA INC.
To: NOKIA CORPORATION
Reel/Frame 032188/0521 →
Assignment of Assignor's Interest
Mar 5, 2014
From: OTVOS, JAMES D.; JEYARAJAH, ELIAS J.; MARKHAM, STEPHEN; MATYUS, STEVEN P.
To: LIPOSCIENCE, INC.
Reel/Frame 032354/0272 →
Assignment of Assignor's Interest
May 5, 2015
From: NOKIA CORPORATION
To: NOKIA TECHNOLOGIES OY
Reel/Frame 035581/0816 →
Change of Name
Sep 4, 2020
From: UNITED TECHNOLOGIES CORPORATION
To: RAYTHEON TECHNOLOGIES CORPORATION
Reel/Frame 054062/0001 →
Corrective Assignment to Correct the and Remove Patent Application Number 11886281 and Add Patent Application Number 14846874. to Correct the Receiving Party Address Previously Recorded at Reel: 054062 Frame: 0001. Assignor(S) Hereby Confirms the Change of Address.
Mar 4, 2021
From: UNITED TECHNOLOGIES CORPORATION
To: RAYTHEON TECHNOLOGIES CORPORATION
Reel/Frame 055659/0001 →
Change of Name
Jul 27, 2023
From: RAYTHEON TECHNOLOGIES CORPORATION
To: RTX CORPORATION
Reel/Frame 064714/0001 →